Stiris Research Completes On-Time Patient Recruitment for Phase I ALS Clinical Trial in Canada and the United States 

Stiris Research Inc., a clinical research organization (CRO) specializing in Phase I–IIIB clinical studies, announces the successful completion of on-time patient recruitment for a Phase I amyotrophic lateral sclerosis (ALS) clinical trial conducted across investigative sites in Canada and the United States. Recruitment for the study was completed in Q1 2026, supporting the advancement of the program into its treatment phase. This milestone positions the study to generate early safety and efficacy data for a disease with no known cure. 

“Recruitment for our Phase I ALS study has been completed on time,” said Shantal Feltham, President & CEO of Stiris Research. “We are extremely grateful to the participants, their families and caregivers, and the investigative sites in Canada and the United States for their collaboration and dedication. We look forward to continued collaboration as we advance to the treatment phase of the study.” 

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons responsible for voluntary muscle movement, including walking, speaking, and breathing. ALS has no known cure, and available treatment options remain limited, making ALS clinical research a critical priority for the neurological and rare disease communities. While most ALS cases are sporadic, the disease remains an area of intense clinical focus due to its severity and limited therapeutic options.  

Completion of recruitment in early-phase neurological clinical trials represents a critical milestone supporting timely study execution, patient retention, site performance, and the continued development of investigational therapies addressing unmet medical needs in ALS.